CLOV
Clover Health Investments, Corp
HOSPITAL & MEDICAL SERVICE PLANS
Clover Health Investments (CLOV) Stock: Buy, Sell, or Hold?
$4.97
+0.04 (+0.81%)
▲
5d:
+5.97%
30d:
+3.33%
90d:
+10.69%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect CLOV Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (49%)
Quality Score
46/100
Position
EXTENDED
30-Day Fair Range
$4.49 – $4.83
Position: EXTENDED
Forward P/E & Valuation
27.6x
CHEAP
vs 34.8x historical avg
Wall Street Target
$5.60
+12.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$4.19 / $5.28
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: CLOV shows conflicting indicators. Wait for confirmation before entering.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Nov 4, 2026 at $4.62 · last confirmed Nov 11, 2026
Strength: 7.0/10
Get Alerted When CLOV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: CLOV is currently trading at $4.97, which is considered extended relative to its 30-day fair value range of $4.49 to $4.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 27.6) compared to its historical average (34.8). Remarkably, the market is currently pricing in an annual earnings decline of 7.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CLOV is in a downtrend. Immediate support is located at $4.19, while resistance sits at $5.28.
Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.60 (+12.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLOV is in a downtrend. Immediate support is located at $4.19, while resistance sits at $5.28.
Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $5.60 (+12.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.49 -
$4.83
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
48.6%
Trading Range & Key Levels
30-Day Trading Range
$4.49 -
$4.83
Current vs Trading Range
EXTENDED
Support Level
$4.19
Resistance Level
$5.28
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding CLOV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (54/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($5.60)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
27.61
Wall Street Target
$5.60
(+12.7%)
Revenue Growth (YoY)
53.1%
Profit Margin
0.4%
Valuation Discount vs History
-7.5% cheaper
PE vs Historical
27.6 vs 34.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.5%
(market-implied from PE analysis)
1-Year Target
$4.60
(-8%)
2-Year Target
$4.25
(-14%)
3-Year Target
$3.93
(-21%)
3-Yr Target (if PE normalizes)
(PE: 28→35)
$4.96
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.6, Growth: 28.6%)
$10.56
(+113%)
Base:
(SPY PE: 19.9, Growth: 28.6%)
$7.60
(+53%)
Bear:
(PE: 16.9, Growth: 28.6%)
$6.46
(+30%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Forward PE: 37.74 | Forward EPS (Implied): $0.13
Bull Case
$6.00
(+21%)
Analyst growth 15.0%, PE expands to 39.6
Base Case
$4.97
(0%)
Market implied 0.0%, PE stable at 37.7
Bear Case
$3.80
(-24%)
Severe decline -15.0%, PE contracts to 34.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.6 to 34.8
Stabilization Target:
$6.26
(+26.0%)
PE Expansion Potential:
+26.0%
Share CLOV Analysis
Share this live CLOV analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (CLOV)
Bullish
6 Retail Mentions
Reddit / WSB Comments
2
Bearish
StockTwits Volume
4 msgs
24h retail stream
Last Tracked
Nov 12, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors are bullish on $CLOV, with some expressing anticipation for a buy opportunity. The latest Yahoo Finance article discusses Nuvation Bio, a financially healthier penny stock with a focus on developing targeted cancer drugs.
Key Retail Themes:
Bullish sentiment towards $CLOV
Discussion of Nuvation Bio and its financial health
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLOV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Healthcare Plans Stocks
Top-rated stocks in Healthcare Plans by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CVS
CVS Health Corp |
STRONG BUY
27 analysts |
$115 | 55 HOLD |
|
UNH
UnitedHealth Group Incor… |
STRONG BUY
26 analysts |
$477 | 51 HOLD |
|
CI
The Cigna Group |
STRONG BUY
24 analysts |
$342 | 52 HOLD |
|
ELV
Elevance Health Inc |
BUY
22 analysts |
$482 | 61 BUY |
|
HUM
Humana Inc |
BUY
26 analysts |
$465 | 43 HOLD |
Advanced CLOV Option Strategies
Professional options setups generated by AI based on today's CLOV price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive CLOV Research Pages
